Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 31;13(1):6522.
doi: 10.1038/s41467-022-34340-3.

Unexpected assembly machinery for 4(3H)-quinazolinone scaffold synthesis

Affiliations

Unexpected assembly machinery for 4(3H)-quinazolinone scaffold synthesis

Xi-Wei Chen et al. Nat Commun. .

Abstract

4(3H)-quinazolinone is the core scaffold in more than 200 natural alkaloids and numerous drugs. Many chemosynthetic methodologies have been developed to generate it; however, investigation of its native enzymatic formation mechanism in fungi has been largely limited to fumiquinazolines, where the two nitrogen atoms come from anthranilate (N-1) and the α-NH2 of amino acids (N-3). Here, via biochemical investigation of the chrysogine pathway, unexpected assembly machinery for 4(3H)-quinazolinone is unveiled, which involves a fungal two-module nonribosomal peptide synthase ftChyA with an unusual terminal condensation domain catalysing tripeptide formation; reveals that N-3 originates from the inorganic ammonium ions or the amide of L-Gln; demonstrates an unusual α-ketoglutarate-dependent dioxygenase ftChyM catalysis of the C-N bond oxidative cleavage of a tripeptide to form a dipeptide. Our study uncovers a unique release and tailoring mechanism for nonribosomal peptides and an alternative route for the synthesis of 4(3H)-quinazolinone scaffolds.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Representative 4(3H)-quinazolinone scaffold-containing drugs and their biosynthetic machinery in natural products.
a Three quinazolinone scaffolds and b the best-selling drugs containing a 4(3H)-quinazolinone scaffold. c 4(3H)-quinazolinone scaffold formation is catalysed by the NRPS CT domain and d α-KGD-mediated rearrangement.
Fig. 2
Fig. 2. Gene clusters and previously proposed pathway for the synthesis of 1.
a Three homologue clusters for the synthesis of 1 in different fungi. b In vivo gene overexpression and knockout experiments in P. chrysogenum and F. graminearum suggested that 3 or its derivatives and 2 are the possible precursors of 1.
Fig. 3
Fig. 3. Confirmation of the ftchy cluster and heterologously produced products.
a LC-MS analyses of the A. nidulans transformant culture extracts. b Chemical structures of the compounds isolated from the AN-ftchyACDEHM transformant. c LC-MS analyses of the AN-ftchyA transformant culture extracts. d Chemical structure of 10 showing it is a linear γ-l-glutamyl-l-alanyl-anthranilate tripeptide.
Fig. 4
Fig. 4. Biochemical confirmation of the unexpected assembly process of ftChyA for the synthesis of 10 and 3.
a Biochemical confirmation of ftChyA synthesizing 10 and 3. b Phylogenetic analysis of fungal NRPS C domains showing that ftChyA-CT is separated into an independent clade. The C domain protein sequences used for phylogenetic analysis are listed in Source Data file. c ftChyA-C1 and ftChyA-CT domain mutations confirm that the C1 domain is responsible for amide bond formation between l-Glu and l-Ala of 10 and that CT is responsible for amide bond formation between l-Ala and Ant to release 10 and 3. d ATP-PPi release assay and MALDI-TOF MS analysis of the A domains for substrate recognition. Data are shown as the mean ± SEM of 3 independent experiments. ***P < 0.001, ****P < 0.0001 (ftChyA-A1, P = 1.5e-6 between l-Glu and Ant, P = 4.5e-6 between l-Glu and l-Ala; ftChyA-A2, P = 0.0008 between l-Ala and Ant), unpaired two-tailed Student’s t test. e Biochemical assays of ftChyA in H218O-Tris buffer confirming that water is not involved in the formation of 10 and 3. f In vitro assays of ftChyA with l-Glu, l-Ala and Ant-Me. The extracted ion chromatograms (EICs) were extracted at m/z 223 [M + H]+ for Ant-Me-3 and m/z 352 [M + H]+ for Ant-Me-10.
Fig. 5
Fig. 5. Three assembly mechanisms of NRPS ftChyA were proposed for the synthesis of 10 and 3.
a Canonical assembly rule of NRPS. b Pass-back mechanism of NRPS. c Proposed mechanism in this study.
Fig. 6
Fig. 6. Biochemical confirmation of the functions of ftChyD, ftChyE and ftChyM.
a ftChyD uses NH4Cl or l-Gln to catalyse the amidation of 10 to form 11. b LC-MS analysis of the incorporation of 15N into 11. The EICs were extracted at m/z 338 [M + H]+ for 10 and 15N-labelled 11, and m/z 337 [M + H]+ for 11. c ftChyE catalyses the hydrolysis of 11 and 10 to form 2 and 3, respectively. d ftChyM is an α-KGD that catalyses the C-N bond oxidative cleavage of 11 to form 4 via a possible intermediate 12. e Conversion of 4 to 6 shows the alkaline-induced spontaneous C-2-N-3 bond closure.
Fig. 7
Fig. 7. The proposed complex pathways for generating the 4(3H)-quinazolinone scaffold in 1 synthesis.
The primary pathway shows unexpected assembly machinery starting from a linear tripeptide and the salvage pathway depends on the promiscuous substrate selectivity of ftchy cluster enzymes.

References

    1. Shang XF, et al. Biologically active quinoline and quinazoline alkaloids part I. Med. Res. Rev. 2018;38:775–828. doi: 10.1002/med.21466. - DOI - PMC - PubMed
    1. Shang XF, et al. Biologically active quinoline and quinazoline alkaloids part II. Med. Res. Rev. 2018;38:1614–1660. doi: 10.1002/med.21492. - DOI - PMC - PubMed
    1. Kshirsagar UA. Recent developments in the chemistry of quinazolinone alkaloids. Org. Biomol. Chem. 2015;13:9336–9352. doi: 10.1039/C5OB01379H. - DOI - PubMed
    1. Khan I, et al. Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: an update on the development of synthetic methods and pharmacological diversification. Bioorgan. Med. Chem. 2016;24:2361–2381. doi: 10.1016/j.bmc.2016.03.031. - DOI - PubMed
    1. Auti PS, George G, Paul AT. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. Rsc. Adv. 2020;10:41353–41392. doi: 10.1039/D0RA06642G. - DOI - PMC - PubMed

Publication types